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By complement fixation, murine oncorna-
virus group specific antigen was identified in
crude extracts of MSV-FBJ sarcomata to-
getherwithsolubleantigensoftype specificity.
The significance of these antigens in
relation to those previously defined for
" wild " type murine leukaemias will be
discussed.
HOST IMMUNE RESPONSES IN
B.C.G. THERAPY OF A RAT OSTEO-
SARCOMA, N. Lawrence and M. Moore,
Charles Salt Research Centre, The Robert
Jones and Agnes Hunt Orthopaedic Hospital,
Oswestry.
The growth of syngeneic grafts of tumour
cells is suppressed when cells are mixed with
B.C.G. before inoculation, or if clinically
established nodules are infiltrated with
microorganisms. Theoretically, three types
of processes operating individually or in
combination might account for this pheno-
menon: (i) non-immune effects; (ii) B.C.G.
immunity and (iii) tumour immunity.
In experiments performed with an immu-
nogenic, chemically induced osteosarcoma,
growth inhibition by B.C.G. was less effective
in rats immunosuppressed by thymectomy
and irradiation than in their immunocom-
petent counterparts. In the study of the
respective roles of immunity to tumour and
B.C.G., the differential radiosensitivity of
primary and secondary immunity permitted
the evaluation of the effect of immunity to
one antigen on a second antigen, to which
primary immunity had been prevented by
interim irradiation.
Evidence will be presented to show that
the host response to B.C.G. is essentially
local and immunological. Tumour out-
growth from B.C.G. tumour cell inocula
occurred with greater frequency in rats
prevented from responding to tumour antigen
than in normal recipients, suggesting that
while local immune reactivity to B.C.G. is a
necessary component of successful tumour
growth inhibition, it is not invariably suffi-
cient.
TUMOUR THERAPY IN DOGS USING
B.C.G., L. N. Owen and D. E. Bostock,
Department of Animal Pathology, School of
Veterinary Medicine, University of Cam-
bridge.
Experimental dogs have been injected
intradermally, intravenously, intrathoracic-
ally and intraperitoneally with percutaneous
B.C.G. vaccine (Glaxo).
Following i.v. injection a patchy inter-
stitial pneumonia has been found with
small granulomata in lungs and liver. There
is lymph node hyperplasia. A small and
transient rise in temperature occurs.
Dogs with osteosarcoma treated surgically
or by x-irradiation have been injected i.v.
with B.C.G. alone or B.C.G. and autologous
tumour cells. Results are encouraging.
Dogs with lymphosarcoma treated by chemo-
therapy and followed by intravenous B.C.G.
alone have not responded well.
Two dogs, one lymphosarcoma and one
osteosarcoma, had anaphylactic shock after
the second B.C.G. injection and an anti-
histamine drug is now routinely given before
the B.C.G.
IMMUNOLOGICAL MECHANISMS IN
CONTROL OF MALIGNANT DI-
SEASE, C. Bone and R. S. Camplejohn,
Departments of Surgery and Pathology,
University of Newcastle upon Tyne.
Cellular immune mechanisms have often
been implicated as important factors in the
restriction and control of neoplastic pro-
liferation. A study wasplannedtoinvestigate
the relationship between cellular immunity,
the rate of malignant cell proliferation and
prognosis in 40 patients with carcinoma of
the rectum.
Cellular immunity was measured by
assessing the patients' delayed hypersensi-
tivity responses to 2-4 dinitrochlorobenzene
(DNCB). The proliferation rates ofthe rectal
carcinomata and the mucosa from which
they arose were measured using an in vivo
stathmokinetic technique (Refsum and Ber-
dal, Tidskr. norske Laegeforen., 1968, 126.
1224).
Each tumour was staged according to its
size and evidence of lymphatic involvement
or metastases. The patients' clinical progress
was followed.
It was found that there was highly signi-
ficant (P > 0-001) relationship between com-
petent cellular immunity and favourable
prognosis. It was also foundthatthe prolifera-
tion rate of the rectal carcinomata was only
halfthat ofthe mucosa from which they arose
and growth was due to a diminished cell loss.
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There was no correlation between the
rates at which the tumours were proliferating
and cellular immune competence.
CELL MEDIATED IMMUNITY IN
CHILDHOOD TUMOURS, S. Kumar,
Christie Hospital, Manchester.
Lymphocytotoxicity tests using the
Hellstr6ms' technique were carried out to
study cell mediated and humoral immunity
in several histological types of childhood
tumour. Tumour type specific lymphocyte
reactivity was detected in most of these
patients; lymphocytes from children Mwith
renal tumours showed a significant cross
reactivity. The degree of lymphocyte
mediated tumour cell killing appeared to be
independent ofthe stage of progression ofthe
tumour. Sera from children with clinically
active tumours blocked the lymphocyto-
toxicity.
A NEW LOOK AT THE EB VIRUS AND
ONCOGENESIS, R. N. P. Sutton, Depart-
ment ofMicrobiology, King's College Hospital
Medical School, London.
The EB virus, a herpes-like DNA virus,
has been associated with malignant disease
(Burkitt's lymphoma, nasopharyngeal carci-
noma) and with infectious mononucleosis and
asymptomatic infections. Spiegelman and
his colleagues (Proc. natn. Acad. Sci. U.S.A.,
1973, 70, 5) have recently detected nucleic
acid homologous with that of the RNA
Rauscher murine leukaemia virus in Burkitt's
lymphoma and nasopharyngeal carcinoma
cells.
This apparent conflict may be resolved
bythe assumption that the temporary depres-
sion of cell mediated immunity which occurs
with EB infection in infectious mono-
nucleosis also occurs in asymptomatic infec-
tions and is the necessary stimulus which
activates an otherwise dormant RNA virus
genome.
Sixty-eight children with acute lympho-
blastic leukaemia were tested for antibodies
to commonly encountered viruses, including
the EB virus; their antibody responses were
normal, indicating intact humoral immunity.
In the case of the EB virus, the antibody
pattern in children tested during the first
month of their leukaemic illness suggested
that a high proportion had experienced
infection with this virus. In view of the
potential immunosuppressive properties of
the EB virus, it is suggested that these
findings mav be related to the leukaemogenic
process.
INDEPENDENT RESPONSES OF
DIFFERENT BINDING SITES ON
EHRLICH ASCITES TUMOUR CELLS
TO TRYPSIN AND TRYPSIN IN-
HIBITOR, P. Whur, Noreen E. Payne and
H. Koppel, The Marie Curie Memorial
Foundation, Oxted.
We previously reported (Whur, Robson
and Payne, Br. J. Cancer, 1973, 28, 80) that
Ehilich ascites tumour cells do not adhere to
mouse host intraperitoneal surfaces unless
treated wvith soybean trypsin inhibitor.
We have subsequently found that the
binding of these cells to NCTC clone 929
mouse cell monolayers in vitro is significantly
enhanced in the presence oftrypsin inhibitor.
However, under the same conditions, adhesion
to plastic surfaces is inhibited by trypsin
inhibitor. Furthermore, incubationoftumour
cells in very low concentrations of trypsin
significantly enhances their adhesion to
plastic surfaces.
These findings suggest that the degree to
wrhich binding sites are expressed is altered by
increasing or decreasing proteolysis of cell
surface components, and that altered proteo-
lysis may suppress the expression of one site
while simultaneously enhancing another.
ULTRASTRUCTURAL AND BIO-
CHEMICAL STUDIES OF THE
EFFECTS OF CONCANAVALIN A ON
LANDSCHUTZ ASCITES TUMOUR
(LAT) CELLS, R. G. P. Pugh-Humphreys
and D. Lawson, Department of Zoology,
University of Aberdeen.
Concanavalin A, a protein which binds
terminal non-reducing o-methyl-D-manno-
pyranosides and o-methyl-D-glucopyrano-
sides (Goldstein, Lucy and Yang, J. Immun.,
1969, 103, 695), agglutinates and induces
functional changes in a variety of cells
(Sharon and Lis, Science, N.Y., 1972, 177,
949) and is cytotoxic to ascites tumour cells
(Inbar, Ben-Basset and Saclis, Int. J. Cancer,
1972, 9, 143).
Concanavalin A treatment of LAT cells
resulted in marked cell agglutination, stimu-
lated 02 uptake and pinocytotic activity
(including pinocytosis of concanavalin A),